Disc Medicine

IRON · NASDAQ

$79.48+$0.55 (+0.70%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $78.93

IRON analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 14 analysts

Average $105.23 (+32.4% upside)

Low: $83.83
Now: $79.48
High: $134.40

Upgrades and downgrades

The latest rating actions, newest first

IRON analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Morgan Stanley	Oct 20, 2026	Maintains	Overweight	$90.00 → $92.00	47%
Truist Securities	Oct 20, 2026	Maintains	Buy	$83.00 → $115.00	36%
Wells Fargo	Oct 20, 2026	Maintains	Overweight	$86.00 → $124.00	54%
Wedbush	Oct 20, 2026	Maintains	Outperform	$100.00 → $110.00	46%
BMO Capital	Oct 19, 2026	Maintains	Outperform	$100.00 → $120.00	54%
Cantor Fitzgerald	Oct 19, 2026	Maintains	Overweight	$125.00 → $170.00	41%
Wells Fargo	Sep 16, 2026	Maintains	Overweight	$79.00 → $86.00	54%
Wedbush	Sep 10, 2026	Maintains	Outperform	$100.00	46%
Wedbush	Sep 2, 2026	Maintains	Outperform	$88.00 → $100.00	46%
HC Wainwright & Co.	Aug 6, 2026	Maintains	Buy	$118.00 → $120.00	50%

The case for and against

Updated Oct 16, 2026

Bull case

Disc Medicine is viewed positively because its lead asset bitopertin has clearer regulatory visibility after the Type A meeting, with APOLLO fully enrolled in March and topline data expected in 4Q26, creating a potential path to resubmission by year-end and an FDA decision by mid-2027. The investment case is further strengthened by evidence that the EPP program may be clinically de-risked, as AURORA showed statistically significant improvements in sunlight tolerance and dose-dependent reductions in metal-free PPIX, while physician feedback suggests meaningful patient benefit. Disc Medicine is also building a broader pipeline with DISC-0974 showing strong Phase 2 signals in anemia of myelofibrosis and DISC-3405 advancing faster than expected in PV, supporting the possibility of multiple pivotal-stage programs in 2027 and reinforcing long-term sales potential.

Bear case

Disc Medicine is burdened by a largely unproven pipeline, with no approved assets and heavy clinical risk across bitopertin, DISC-0974, and DISC-3405, each assigned only partial probabilities of success that reflect uncertainty in efficacy, safety, and regulatory outcomes. Its commercial case is also weak because it has never launched a product, is entering competitive markets, and may face reimbursement pressure, while the company is likely to need additional funding despite cash, cash equivalents, and marketable securities of $717.7M expected to support operations only through 2029. Although 2Q loss per share of $1.54 beat estimates and R&D fell a bit above expectations at $46.9M, the $65.1M operating loss and rising SG&A underscore persistent spending before any meaningful revenue emerges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.